Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00607763 · ClinicalTrials.gov registry record · Phase 1
Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
A Phase 1 study of Candidemia and Invasive Candidiasis, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 6
- Study locations
NCT00607763 is a Phase 1 study of Candidemia and Invasive Candidiasis that has completed, run by Astellas Pharma. The registered enrollment target is 9 participants, below the 413-participant average among 8 other Candidemia trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT00607763, a Phase 1 study of Candidemia and Invasive Candidiasis, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 6
- Study locations
Study Summary
Infants and toddlers with fungal infections will receive 10 to 14 days of treatment with an antifungal drug. Safety and drug blood levels will be assessed
Conditions Studied
Interventions
- DRUG Micafungin (Mycamine)
Study Locations (6)
California
- - Los Angeles
- - Orange
Texas
- - Dallas
- - Houston
Kentucky
- - Louisville
Missouri
- - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00607763
The ClinicalTrials.gov registry entry for NCT00607763 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 413-participant average among 8 other Candidemia trials with a reported enrollment target (98% lower). The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Candidemia appearing as the primary indexed condition, and to 1 intervention - of which Micafungin (Mycamine) is the first listed.
NCT00607763 reports 6 study locations spanning 4 distinct geographic areas - top geographies include California, Texas, Kentucky.
Frequently Asked Questions
What is clinical trial NCT00607763 about?
NCT00607763 is a clinical study titled "Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug". Infants and toddlers with fungal infections will receive 10 to 14 days of treatment with an antifungal drug. Safety and drug blood levels will be assessed
What is the current status of trial NCT00607763?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2007-10. Estimated completion is 2009-10.
What conditions does trial NCT00607763 study?
This clinical trial studies the following conditions: Candidemia, Invasive Candidiasis, Oropharyngeal Candidiasis, Esophageal Candidiasis.
What interventions are being tested in trial NCT00607763?
The interventions under investigation include: Micafungin (Mycamine) (DRUG).
Who is sponsoring clinical trial NCT00607763?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00607763 being conducted?
This trial has 6 study locations across California, Kentucky, Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Candidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
COMPLETED · Phase 1
-
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
RECRUITING · Phase 3
-
Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia
RECRUITING · Phase 2
-
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
ACTIVE NOT RECRUITING · Phase 3
-
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
COMPLETED · Phase 3
-
Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.